Skip to main content
Top
Published in: Infection 3/2018

01-06-2018 | Brief Report

2016 PREP attitudes in Germany: high awareness and acceptance in MSM at risk of HIV

Authors: Christoph D. Spinner, Nikola Hanhoff, Ivanka Krznaric, Gaby Knecht, Tim Kuemmerle, Robin Ruesenberg, Knud Schewe

Published in: Infection | Issue 3/2018

Login to get access

Abstract

Prupose

To examine current risk behavior, awareness, experience, and attitudes towards pre-exposure-prophylaxis (PrEP), and to estimate a potential impact on the prevention of HIV transmission among HIV-negative MSM in Germany. PrEP was not officially licensed at the time of survey.

Methods

Web-based questionnaire from 03–06/2016. Potential participants were informed through social media, flyers, and advertisements. Risk contacts were defined as unprotected sexual intercourse under the influence of recreational drugs in the past 6 months.

Results

In total, 1208 subjects participated, 342 subjects were excluded for being HIV-infected or non-MSM, leaving 866 subjects to be evaluated in this analysis. Mean age was 37.0 ± 10.4 years. 593 participants (68.5%) were tested for HIV within the past 12 months. A total of 206 STDs in the past 6 months were reported by 144 (16.6%). Aware of PrEP was 748 (86.4%) respondents, while 65.1% reported willingness to use it. Risk behavior was significantly associated with higher PrEP acceptance (OR 2.90, 95% CI 2.14–3.90), as was a history of STDs (OR 1.85, 95% CI 1.17–2.91). The use of condoms would forgo 52.3% of subjects if taking PrEP. Sixty-five respondents (7.5%) reported PrEP use. Only 19 (29.2%) had accessed PrEP under medical supervision. PrEP use was reported by 14.8% with > 5 risk contacts in the past 6 months, compared to 6.3% with one risk contact (p < 0.001).

Conclusion

We found a high PrEP awareness and acceptance, especially among subgroups of MSM at highest risk of HIV infection. Structured access and availability of PrEP to this population may have an important impact on the HIV epidemic in Germany.
Literature
1.
go back to reference Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8.CrossRefPubMed Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink H-J, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44:151–8.CrossRefPubMed
2.
go back to reference Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46.CrossRefPubMed Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373:2237–46.CrossRefPubMed
3.
go back to reference McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet Lond Engl. 2016;387:53–60.CrossRef McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet Lond Engl. 2016;387:53–60.CrossRef
6.
go back to reference European Centre for Disease Prevention and Control. Evidence brief: pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2016. p. 1–8. European Centre for Disease Prevention and Control. Evidence brief: pre-exposure prophylaxis for HIV prevention in Europe. Stockholm: ECDC; 2016. p. 1–8.
7.
go back to reference Knecht G, Hanhoff N, Bodtländer A, Ingiliz P, Krznaric I. Attitudes towards pre-exposure prophylaxis (PrEP) among MSM in Germany [abstract MOPE132]. Kuala Lumpur, Malaysia: 7th IAS Conference 2013. Knecht G, Hanhoff N, Bodtländer A, Ingiliz P, Krznaric I. Attitudes towards pre-exposure prophylaxis (PrEP) among MSM in Germany [abstract MOPE132]. Kuala Lumpur, Malaysia: 7th IAS Conference 2013.
8.
go back to reference Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4:e402–10.CrossRefPubMed Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4:e402–10.CrossRefPubMed
9.
go back to reference Russel D. Epidemiology of STIs in the HIV and AIDS era. 9th IAS Conference Paris 2017. Russel D. Epidemiology of STIs in the HIV and AIDS era. 9th IAS Conference Paris 2017.
10.
go back to reference Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65:712–8.CrossRef Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017;65:712–8.CrossRef
Metadata
Title
2016 PREP attitudes in Germany: high awareness and acceptance in MSM at risk of HIV
Authors
Christoph D. Spinner
Nikola Hanhoff
Ivanka Krznaric
Gaby Knecht
Tim Kuemmerle
Robin Ruesenberg
Knud Schewe
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 3/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-018-1127-3

Other articles of this Issue 3/2018

Infection 3/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.